Previous 10 | Next 10 |
WALTHAM, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that new and encore data related to bremelanotide and Hypoactive Sexual Desire Disorder (HSDD) will be presented at the upcoming International Society for the Study of Women's Sexual ...
WALTHAM, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the following investor conferences during the month of March: Cowen and Company 39 th Annual Health Care Conference Monday, March 11, 2...
Palatin Technologies ( PTN ) has successfully developed bremelanotide, a drug that deals with the problem of hypoactive sexual desire disorder (HSDD) in women. However, due to the recent FDA extension of its review date, Palatin stock price suffers from a huge decline. The new action date is e...
WALTHAM, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Ted Myles, chief financial officer and Julie Krop, MD, chief medical officer will participate in a fi...
AMAG Pharmaceuticals, Inc. (AMAG) Q4 2018 Earnings Conference Call February 7, 2019 8:00 AM ET Company Participants Linda Lennox – Vice President, Investor Relations Bill Heiden – President and Chief Executive Officer Nik Grund – Chief Commercial Officer Ju...
AMAG Pharmaceuticals ( AMAG ) Q4 results : Revenues: $88.1M (-31.4%); Makena: $46.9M (-53.3%); Feraheme/MuGard: $35.3M (32.7%); Intrarosa: $5.9M (293.3%). More news on: AMAG Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
AMAG Pharmaceuticals (NASDAQ: AMAG ): Q4 GAAP EPS of -$0.60 beats by $0.33 . More news on: AMAG Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Reaffirms 2019 Financial Guidance and Announces Consolidation of Women’s Health and Maternal Health Sales Forces Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported ...
ADNT , ADS , AMAG , ANDX , ARW , BCE , BR , BSIG , BV , CAH , CDW , CEIX , CNHI , COR , DNKN , DTE , EIGI , EPC , FCAU , GRA , GRUB , HAIN , HBI , ICE , K , LCII , LH , MAC , MAS , MD , MMS , MPC , MPLX , MPW , ODFL , PAG , PBH , PENN , PM , PRLB , P...
WALTHAM, Mass., Jan. 30, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its fourth quarter and full year 2018 financial results will be released on Thursday, February 7, 2019 before the U.S. financial markets open. Management will host a conference c...
News, Short Squeeze, Breakout and More Instantly...
AMAG Pharmaceuticals Inc. Company Name:
AMAG Stock Symbol:
NASDAQ Market:
AMAG Pharmaceuticals Inc. Website:
WALTHAM, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its response to the FDA’s Notice of Opportunity for a Hearing (“NOOH”) regarding the Agency’s proposal to withdraw approval for Makena—also referred to as 17-OHP...
MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600 MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&...
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug Administration’s (FDA) proposal to withdraw its approval of Makena ® , the only F...